KOSDAQBiotech & Pharma060280

Curexo

₩6,530▲ 5.15%2026-11-18 close
Market Cap
₩269.4B
Turnover
₩1.4B
Volume
220K
Shares out.
41.3M
PER
210.0×
PBR
2.8×
EPS
₩32
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Recovery Meets Quarterly Losses

Curexo returned to operating profit and net profit attributable to controlling shareholders for 2025, but an operating loss in the third quarter of 2026 has put quarterly volatility at the center of the story.

  1. 1

    Sales reached KRW 74.5 billion in 2025, the largest year in the 2022–2025 span, and operating profit of KRW 2.36 billion marked a return to profit.

  2. 2

    Third-quarter 2026 sales fell 14.4% year on year to KRW 14.7 billion, with an operating loss of KRW 1.88 billion and a net loss attributable to controlling shareholders of KRW 3.35 billion.

  3. 3

    A CUVIS-joint sales contract worth KRW 8.46 billion was disclosed in May 2026, running through December 31, 2026.

  4. 4

    Net profit attributable to controlling shareholders over the last four quarters (Q4 2025 to Q3 2026) totals KRW 1.34 billion, close to half of the KRW 2.77 billion reported for 2025 as a full year.

  5. 5

    Operating cash flow was -KRW 11.3 billion in 2025, diverging from the return to profit, so the cash flow structure in the next annual report is a key checkpoint.

02

Business structure

Curexo is a medical robotics company whose core business is surgical robots for orthopedic procedures. Its flagship product is the CUVIS-joint robot for knee arthroplasty, and the company disclosed a sales contract for the product on May 20, 2026. The counterparty is Biorad Medisys Pvt.

Ltd., and the contract amount is KRW 8.46 billion, equal to about 11.4% of the KRW 74.5 billion in recent annual sales. The contract period runs from May 19, 2026 to December 31, 2026, roughly seven months.

In its 2025 third-quarter cumulative results, the company said cumulative medical robot sales rose 80% year on year and attributed this to broadening its sales countries, including Japan, Taiwan, Indonesia, Malaysia and Pakistan.

The same release said India, where sales were temporarily weak the prior year, is recovering. A stock information site (AlphaSquare, as shown in late October 2026) tallies sales mix with domestic goods at 54.09%, the largest share, followed by exported products at 33.75% and domestic products at 11.70%.

That classification follows the site's own method and may not map directly onto the segment split in company filings. Export-related items account for a little more than one-third of the total, so results depend on hospital investment capacity and local healthcare systems in each country. Competitively, Curexo contests hospital adoption with leading global orthopedic robot makers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩17.2B₩300M2.0%
2025Q4₩20.8B₩1.4B6.6%
2026Q1₩16.1B-₩900M−5.7%
2026Q2₩23.6B₩2.4B10.3%
2026Q3₩14.7B-₩1.9B−12.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩65B₩1.1B-₩3B1.7%−3.7%20.5%
2023₩72.9B₩1.1B-₩4.9B1.6%−4.8%6.9%
2024₩55.5B-₩5.8B-₩8.8B−10.5%−9.4%9.9%
2025₩74.5B₩2.4B₩2.8B3.2%2.9%5.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales rose from KRW 65 billion in 2022 to KRW 72.9 billion in 2023, up 12.1% year on year, then fell to KRW 55.5 billion in 2024, down 23.8%. Sales rebounded to KRW 74.5 billion in 2025, up 34.2%, the largest year in the 2022–2025 span.

Operating profit was small at KRW 1.11 billion in 2022 and KRW 1.14 billion in 2023, up 2.2%, before turning into an operating loss of KRW 5.82 billion in 2024. The operating margin fell to -10.5% in 2024 and recovered to 3.2% in 2025.

In 2025 operating profit of KRW 2.36 billion and net profit attributable to controlling shareholders of KRW 2.77 billion both turned positive. Net profit including non-controlling interests was also KRW 2.77 billion in 2025.

Net losses attributable to controlling shareholders widened in 2023 and 2024, reaching KRW 8.76 billion in 2024. The debt-to-equity ratio fell to 5.1% in 2025 from 20.5% in 2022, with total liabilities of KRW 4.89 billion and total equity of KRW 96.2 billion. Quarterly results swing sharply.

Sales of KRW 17.2 billion and operating profit of KRW 341 million in the third quarter of 2025 gave way to sales of KRW 20.8 billion and operating profit of KRW 1.38 billion in the fourth quarter.

The first quarter of 2026 showed sales of KRW 16.1 billion and an operating loss of KRW 913 million, while the second quarter returned to profit with sales of KRW 23.6 billion and operating profit of KRW 2.44 billion.

The third quarter of 2026 reported sales of KRW 14.7 billion and an operating loss of KRW 1.88 billion, and the net loss attributable to controlling shareholders of KRW 3.35 billion was larger than the operating loss, so non-operating items and taxes need to be read alongside it.

Operating cash flow was -KRW 13.1 billion in 2022, KRW 5.08 billion in 2023, KRW 3.85 billion in 2024 and -KRW 11.3 billion in 2025, moving in a direction that diverges from the profit trend.

05

Industry analysis

Demand for orthopedic surgical robots is driven by the growth in degenerative joint disease that comes with an aging population. Robot-assisted surgery is gaining hospital adoption because it improves the precision of bone cutting and implant placement.

Equipment demand, unlike consumables, depends on hospitals' capital spending timing, which tends to make quarterly revenue lumpy. Adoption timing varies with hospital investment capacity, insurance systems and each country's medical infrastructure.

In global markets, leading American players hold large hospital and training networks, so smaller companies often enter through price competitiveness and local distribution partners.

Curexo has pursued this route by widening its overseas sales countries, which according to its 2025 release now include Japan, Taiwan, Indonesia, Malaysia and Pakistan. Domestically, adoption has centered on large general hospitals, and order intake moves irregularly with individual hospital purchasing decisions.

The company describes India as recovering from a temporary slump the prior year, and whether that demand is sustained should be confirmed through coming quarterly results. Within the domestic medical robotics field, Curexo sits among a small group of companies specializing in joint arthroplasty robots.

06

Outlook

The closest order disclosed with a company-stated basis is the CUVIS-joint sales contract announced in May 2026. Its KRW 8.46 billion value equals about 11.4% of recent sales, and the contract period ends on December 31, 2026.

How this contract is recognized as revenue can be gauged from sales trends in the fourth quarter of 2026 and the 2026 annual report.

Second-quarter 2026 sales were high at KRW 23.6 billion, but third-quarter sales fell to KRW 14.7 billion, suggesting that the timing gap between orders and revenue recognition is affecting the results.

Because diversification of overseas sales countries was cited as the main driver of improvement in the 2025 cumulative results, whether this trend continues in 2026 is important. Whether India's recovery holds is a checkpoint in the same context.

The operating margin recovered to 3.2% in 2025, but operating losses in the first and third quarters of 2026 mean the duration of profitable stretches is the central question for the next periodic report.

The 2026 annual report will disclose the fourth-quarter results and full-year totals, along with working capital movements in the cash flow statement. The cause of the 2025 operating cash flow of -KRW 11.3 billion, which diverges from profit, should be verified in that data.

No company annual targets are cited here because there is no public basis to report them. Any comparison of results against market expectations should rest on disclosed figures.

07

Valuation

PER
210.0×
PBR
2.8×
ROE
1.4%
EPS
₩32
BPS
₩2,385
Dividend per share
₩0

Valuation should be read alongside the size of earnings. Net profit attributable to controlling shareholders over the last four quarters totals only KRW 1.34 billion, so the current price multiple sits high relative to that earnings base.

Compared with the KRW 2.77 billion reported for 2025 as a full year, the last four quarters total is close to half. On the balance sheet, total equity of KRW 96.2 billion at year-end 2025, all attributable to controlling shareholders, means the price-to-book multiple reflects a premium over net assets.

Total liabilities of KRW 4.89 billion keep financial burden small. The company shows no current dividend payment record, so the dividend yield is low and dividends cannot easily anchor valuation.

Comparison with past multiple bands depends on where the share price stands at each date, so the position relative to the upper and lower bounds should be checked for each period.

After the return to profit in 2025 and the operating loss in the third quarter of 2026, the fourth-quarter trend in the next annual report is the key variable for reading the multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Expanding overseas sales countries

The company said cumulative medical robot sales in the 2025 third quarter rose 80% year on year. It attributed the increase mainly to new sales countries including Japan, Taiwan, Indonesia, Malaysia and Pakistan. The company also said India sales are recovering from a temporary slump the prior year. A broader overseas base can reduce the impact of irregular domestic hospital purchasing.

A 2025 turn from losses to profit

Operating results moved from an operating loss of KRW 5.82 billion in 2024 to operating profit of KRW 2.36 billion in 2025. The operating margin improved from -10.5% in 2024 to 3.2% in 2025. Net profit attributable to controlling shareholders also turned positive at KRW 2.77 billion. A debt-to-equity ratio of 5.1% leaves room on the capital structure side.

Large sales contract in hand

The CUVIS-joint sales contract disclosed on May 20, 2026 is worth KRW 8.46 billion, about 11.4% of recent sales. The counterparty is Biorad Medisys Pvt. Ltd., and the contract runs through December 31, 2026. It shows continued overseas orders for the knee arthroplasty robot. How revenue is recognized during contract execution is a checkpoint for later quarterly results.

09

Bear factors

Recurring quarterly losses in 2026

The first quarter of 2026 turned into an operating loss of KRW 913 million, and the third quarter also posted an operating loss of KRW 1.88 billion. The third-quarter net loss attributable to controlling shareholders was KRW 3.35 billion, larger than the operating loss.

Net profit attributable to controlling shareholders over the last four quarters totals only KRW 1.34 billion, so earnings stability is low. A single profitable quarter does not confirm the annual trend.

Weak operating cash flow

Operating cash flow showed large outflows in both 2022, at -KRW 13.1 billion, and 2025, at -KRW 11.3 billion. Despite operating profit in 2025, operating cash flow was negative. It was positive in 2023 and 2024, so the year-to-year swings are large. Profit and cash not moving in the same direction is a burden when assessing earnings quality.

High multiples on a thin earnings base

With a small earnings base, the share price multiple is high, so even small swings in profit change how the multiple reads. The last four quarters total is close to half the KRW 2.77 billion reported for 2025 as a full year. With no current dividend record, shareholder return support is limited. The premium over net assets can also weigh on the valuation.

10

Risk factors

Earnings volatility

Quarterly sales moved sharply, from KRW 20.8 billion in the fourth quarter of 2025 to KRW 16.1 billion in the first quarter of 2026, KRW 23.6 billion in the second and KRW 14.7 billion in the third. Operating results alternated between profit and loss by quarter.

Equipment sales tend to cluster around hospital purchase timing, which makes trends hard to read from single quarters. Annual figures are the more reliable basis for interpretation.

Overseas demand and country concentration

Export-related items make up a little more than one-third of total sales, and the expansion of sales countries cited as a main driver could rest on demand in a few countries. The company describes India as recovering after a temporary slump the prior year, but whether that continues remains to be seen. Local healthcare systems and exchange rate moves can affect sales flows.

Order execution and revenue timing

The KRW 8.46 billion sales contract disclosed in May 2026 runs through December 31, 2026, so its execution and revenue recognition could span quarter boundaries. A disclosed contract amount does not translate directly into quarterly revenue. Delays in execution could widen quarterly swings. How much of the contract value shows up in reported revenue should be checked in the annual report.

11

What to watch next

  1. December 31, 2026

    The contract period for the CUVIS-joint sales agreement with Biorad Medisys Pvt. Ltd. ends. Whether follow-on orders are disclosed around this date and how revenue is reflected are the next checkpoints.

  2. Mid-March 2027

    The 2026 annual report is expected around this time, based on last year's timing in mid-March. The fourth-quarter 2026 results, full-year totals and whether the operating margin stays positive are the key checkpoints.

  3. Mid-March 2027 (within the annual report)

    The operating cash flow and working capital movements in the annual report are the checkpoints. The cause of the 2025 operating cash flow of -KRW 11.3 billion, which diverged from profit, and country-level overseas sales trends in 2026 can be checked together.

  4. Mid-May 2027

    The first-quarter 2027 results are due around this time, based on last year's first-quarter timing. Sales scale and the direction of operating results in that quarter will indicate whether the 2026 quarterly pattern continues.

12

Overall view

Curexo turned profitable for the full year 2025, with sales of KRW 74.5 billion, operating profit of KRW 2.36 billion and net profit attributable to controlling shareholders of KRW 2.77 billion. Overseas sales country expansion and the CUVIS-joint sales contract are cited as growth drivers.

On the other side, operating losses appeared in the first and third quarters of 2026, and the third-quarter net loss attributable to controlling shareholders reached KRW 3.35 billion.

Net profit attributable to controlling shareholders over the last four quarters totals KRW 1.34 billion, and operating cash flow in 2025 was -KRW 11.3 billion. With the share price multiple high relative to the earnings base, earnings volatility directly affects how the multiple reads.

Given quarterly results alternating between profit and loss, the next checkpoints are the fourth-quarter results and cash flows in the 2026 annual report. This report presents no investment rating, recommendation or target price and is intended only as factual information based on disclosures.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. hankyung.com
  2. news.nate.com
  3. alphasquare.co.kr
  4. littlebproject.com
  5. investing.com
  6. kpinfo.kr
  7. investing.com
  8. judal.co.kr
  9. stocktitan.net
  10. financialcontent.com
  11. newspim.com
  12. finance.yahoo.com
  13. investors.qxo.com
  14. gurufocus.com
  15. kucoin.com
  16. curexo.com
  17. edaily.co.kr
  18. datatooza.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis